BridgeBio Pharma, Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001743881-26-000019
- Form type
- 10-Q
- CIK
- 0001743881
- Primary document
- https://www.sec.gov/Archives/edgar/data/1743881/000174388126000019/bbio-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for BridgeBio Pharma, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $194.5M | - | - |
| Cost Of Revenue | $9.9M | - | - |
| Operating Income | $-106.0M | - | - |
| Eps Basic | -0.84 | - | - |
| Eps Diluted | -0.84 | - | - |
| Cash And Equivalents | $879.9M | - | - |
| Total Assets | $1.4B | - | - |
| Total Liabilities | $3.6B | - | - |
| Shareholders Equity | $-2.3B | - | - |
| Operating Cash Flow | $-197.3M | - | - |
| Capital Expenditures | $69,000 | - | - |